According to a comparison of drug sensitivity versus the percentage parasitemia curves (Figure 4a), PYR is recognized as a DHFR inhibitor drug that is a potent anti-malarial agent (IC50 = 0.046 μM). This evidence concerns the gene DHFR and parasitic infectious disease.